---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-23-000085"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T08:56:29.611904+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pacira appoints Frank D. Lee as CEO effective Jan 2, 2024; Stack retires to advisory role

## Summary
- Frank Lee named CEO and Board member, effective Jan 2, 2024; prior CEO of Forma Therapeutics.
- David Stack retires as CEO and Chairman, remains as advisor through August 2025.
- Paul Hastings, Lead Independent Director, elected Chair of the Board effective Jan 2, 2024.
- Lee's compensation: $900k base salary, 85% bonus target, 692,512 options, 99,520 RSUs as inducement awards.
- Pacira Amended 2014 Inducement Plan to reserve 817,093 shares; term extended to Dec 20, 2033.

## SEC filing metadata
- accession: 0001396814-23-000085
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000085/0001396814-23-000085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000085/pcrx-20231220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-23-000085
- JSON: https://secwatch.observer/filing/0001396814-23-000085.json
- Plain text: https://secwatch.observer/filing/0001396814-23-000085.txt

## Key facts
- Executive change
  David Stack retired as Chief Executive Officer at Pacira BioSciences, Inc..
  - Action: retired
  - Role: Chief Executive Officer
  source text: David Stack informed the Board of Directors (the "Board") of Pacira BioSciences, Inc. (the "Company") that he intended to retire as Chief Executive Officer of the Company and as a member of the Board effective immediately following the appointment of his successor as Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000085/0001396814-23-000085-index.htm
- Executive change
  Frank Lee was appointed as Chief Executive Officer at Pacira BioSciences, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the Board appointed Frank Lee as Chief Executive Officer of the Company and as a member of the Board, effective January 2, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000085/0001396814-23-000085-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.